Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib and Dalpiciclib in HR+/HER2- Advanced Breast Cancer
NCT06612814Phase 3Active, not recruiting
- Sponsor
- Zhimin Shao
- Start
- Sep 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluzoparib in breast cancer (2 arms), sponsored by Zhimin Shao. Primary endpoint: Progression-Free Survival at 5 years. Started Sep 2024; status: active, not recruiting.
02
Drugs
fluzoparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06612814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06612814.